Login / Signup

Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.

William C DougallAmelia Roman AguileraMark J Smyth
Published in: Clinical & translational immunology (2019)
In summary, the bispecific anti-RANKL/PD-1 antibody demonstrates potent tumor growth inhibition in settings of ICI resistance and represents a novel modality for clinical development in advanced cancer.
Keyphrases
  • advanced cancer
  • palliative care
  • nuclear factor
  • bone loss
  • cancer therapy
  • anti inflammatory
  • drug delivery